John Lim's third consecutive term as CEO of Samsung Biologics has been virtually confirmed.
According to the bio industry on December 30, Samsung Biologics recently decided to reappoint John Lim as CEO at a board meeting. The reappointment is expected to be finalized at the regular general shareholders' meeting in March next year.
Having taken office in December 2020, John Lim will now begin his third term.
During his tenure, Samsung Biologics has been recognized for remarkable growth both quantitatively and qualitatively. In 2022, the company became the first Korean bio company to surpass 3 trillion won in sales, and last year, it exceeded 4 trillion won.
The market attributes this achievement to the company's rapid adaptation to a rapidly changing environment, marked by the significant expansion of global big pharma clients and increased production capacity.
Recently, Samsung Biologics acquired a production facility in Rockville, Maryland, USA, for $280 million (approximately 413.6 billion won).
With this acquisition, Samsung Biologics now boasts the world's largest production capacity, totaling 845,000 liters. The company plans to complete its second bio campus by 2032, aiming to secure a "super-gap" production capacity of 1,385,000 liters.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
